Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) EBIT (2016 - 2024)

Trinity Biotech's EBIT history spans 16 years, with the latest figure at -$11.5 million for Q4 2024.

  • On a quarterly basis, EBIT fell 204.66% to -$11.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$21.2 million, a 21.76% increase, with the full-year FY2025 number at -$15.8 million, up 25.4% from a year prior.
  • EBIT hit -$11.5 million in Q4 2024 for Trinity Biotech, down from -$2.6 million in the prior quarter.
  • Over the last five years, EBIT for TRIB hit a ceiling of $9.1 million in Q3 2020 and a floor of -$14.9 million in Q2 2023.
  • Historically, EBIT has averaged -$2.0 million across 5 years, with a median of -$2.2 million in 2022.
  • Biggest five-year swings in EBIT: surged 581.55% in 2020 and later crashed 1548.85% in 2022.
  • Tracing TRIB's EBIT over 5 years: stood at $9.1 million in 2020, then crashed by 93.79% to $563000.0 in 2021, then crashed by 1548.85% to -$8.2 million in 2022, then skyrocketed by 53.67% to -$3.8 million in 2023, then tumbled by 204.66% to -$11.5 million in 2024.
  • Business Quant data shows EBIT for TRIB at -$11.5 million in Q4 2024, -$2.6 million in Q3 2024, and -$4.1 million in Q2 2024.